Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA versus DARVOCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA versus DARVOCET.
ANEXSIA vs DARVOCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Darvocet is a combination of propoxyphene, a mu-opioid receptor agonist that alters perception of and response to pain, and acetaminophen, which inhibits COX enzymes and modulates descending serotonergic pathways.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
1 tablet (propoxyphene 100 mg / acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Propoxyphene: 6-12 hours (parent), 30-36 hours (norpropoxyphene). Acetaminophen: 1-4 hours (therapeutic doses). Accumulation of norpropoxyphene occurs with repeated dosing.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Propoxyphene: primarily hepatic metabolism to norpropoxyphene, renal excretion of metabolites (<1% unchanged). Acetaminophen: renal excretion of conjugates (85-90%) and unchanged drug (2-4%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination